3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
4
Cisplatin
3
Carboplatin
3
budigalimab
2
Pemetrexed
2
Paclitaxel
2
Immunotherapy
2
Etoposide
2
Drug Therapy
2
Docetaxel
2
Cyclophosphamide
2
venetoclax
1
trametinib
1
spartalizumab
1
sargramostim
1
rovalpituzumab tesirine
1
ribociclib
1
poly ICLC
1
fludarabine
1
enzalutamide
1
entinostat
1
belinostat
1
UV1 vaccine
1
Tomography, Optical Coherence
1
Thrombopoietin
1
Sunitinib
1
Sirolimus
1
Quality of Life
1
Polymerase Chain Reaction
1
Patient Reported Outcome Measures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Blood Component Removal
×
Other solid neoplasm
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled